[Aromatase inhibitors and arthralgia].

In several large adjuvant clinical trials it has been demonstrated that substitution (eventually addition) of aromatase inhibitors (AIs) provides an improved outcome of endocrine-sensitive breast cancer over tamoxifen alone. Nevertheless, arthralgia induced by the AIs is one of the most frequent side effects in hormonal therapy. It is characterized by tenosynovial changes and is more frequent in patients in clinical practice than previously appreciated in adjuvant clinical trials.

[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].

The treatment of recurrent, progressing, metastatic breast cancer, which has previously been exposed to anthracyclines and/or taxanes is not only a major clinical challenge, but has a significant social impact too. In the absence of formal guidelines, this review has aimed to summarize the published evidence that is needed to guide clinical decision-making. Four new agents are approved for use in this setting: capecitabine, gemcitabine, ixabepilone, and nanoparticle albumin-bound paclitaxel.

Influence of fadAG203R and deltaflbA mutations on morphology and physiology of submerged Aspergillus nidulans cultures.

Morphologic and physiologic changes taking place in carbon-limited submerged cultures of Aspergillus nidulans deltaflbA and fadAG203R strains were studied. Loss-of-function mutation of the flbA gene resulted in an altered germination with unusually thick germination tubes, "fluffy" pellet morphology, as well as a reduced fragmentation rate of hyphae during autolysis. In the fadAG203R mutant strain, conidiophores formed in the stationary phase of growth, and the size of pellets shrank considerably.